comparemela.com

Latest Breaking News On - Rona yaeger - Page 1 : comparemela.com

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

STARMAP is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer therapies BBI-825 is a novel, oral, selective ribonucleotide.

San diegoUnited statesRona yaegerKlaus wagnerZachary hornbyExchange commissionBoundless bioChief medical officerGastrointestinal oncologistEarly drug development specialistMemorial sloan kettering cancerChief executive officerTreating acquired resistancePrivate securities litigation reform act

Dr Yaeger on the Implications of Data With Second-Line Sotorasib Plus Panitumumab in mCRC

Rona Yaeger, MD, discusses the implications of data with second-line sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Rona yaegerMemorial sloan kettering cancer centerNational comprehensive cancer networkCancers symposiumMemorial sloan kettering cancer centerOnclive tvColorectal cancer

Dr Yaeger on the Background of the CodeBreaK 101 Trial in mCRC

Rona Yaeger, MD, discusses the rationale for launching an expansion cohort study based on findings from the CodeBreaK 101 study.

Rona yaegerMemorial sloan kettering cancer centerMemorial sloan kettering cancer centerOnclive tvColorectal cancer

KRAS G12C–Targeted Therapies May Move Earlier in the mCRC Treatment Sequence

Rona Yaeger, MD, discusses a study of second-line sotorasib plus panitumumab in patients with KRAS G12C–mutated colorectal cancer.

Memorial sloan kettering cancer centerNew yorkUnited statesRona yaegerNational comprehensive cancer networkClinical practice guidelinesColon cancerSecond line sotorasib plus panitumumabPatients with kras g12c mutated colorectal cancer

Targeted Colorectal Cancer Combo Improves QoL

Patients with metastatic colorectal cancer who have the KRAS G12C mutation demonstrated improved quality of life following sotorasib and panitumumab compared with standard therapy.

Memorial sloan kettering cancer centerNew yorkUnited statesRona yaegerUniversity of medicineEuropean organisation for researchNew england journalBrief pain inventoryEuropean organisationCancer corePatient global impressionColorectal cancerColorectal cancer crcMetastatic colorectal cancerMetastatic crcEtastatic colorectal cancer mcrc

vimarsana © 2020. All Rights Reserved.